%0 Journal Article
%T Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
%A Alessandro Leonetti
%A Francesco Leonardi
%A Melissa Bersanelli
%A Sebastiano Buti
%J Archive of "Therapeutics and Clinical Risk Management".
%D 2017
%R 10.2147/TCRM.S126910
%X Renal cell carcinoma (RCC) represents 2%¨C3% of all cancers in adults, and its pathogenesis is mainly related to altered cellular response to hypoxia. Lenvatinib, a novel multitarget tyrosine kinase inhibitor (TKI), represents a therapeutic option, in combination with mammalian target of rapamycin (mTOR) inhibitor everolimus, for the treatment of metastatic RCC (mRCC)
%K lenvatinib
%K everolimus
%K evidence-based review
%K renal cell carcinoma
%K RCC
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499780/